Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.

Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schackert HK, Saeger HD, Klöppel G, Pilarsky C.

Br J Cancer. 2004 Mar 8;90(5):1053-8.

2.

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.

Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Röder C, Kalthoff H, Röcken C, Sipos B, Kabelitz D, Schäfer H, Oberg HH, Wesch D, Sebens S.

PLoS One. 2014 May 5;9(5):e94357. doi: 10.1371/journal.pone.0094357. eCollection 2014.

3.

Utilization of CDX2 expression in diagnosing pancreatic ductal adenocarcinoma and predicting prognosis.

Xiao W, Hong H, Awadallah A, Zhou L, Xin W.

PLoS One. 2014 Jan 29;9(1):e86853. doi: 10.1371/journal.pone.0086853. eCollection 2014.

4.

Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.

Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS.

Am J Surg Pathol. 2010 Apr;34(4):510-8. doi: 10.1097/PAS.0b013e3181cfcac7.

PMID:
20182344
5.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.

PMID:
25445504
6.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
7.

New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.

Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, Goggins M, Hruban RH.

Am J Surg Pathol. 2008 Feb;32(2):188-96. doi: 10.1097/PAS.0b013e31815701f3.

8.

DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.

Sun J, Bi F, Yang Y, Zhang Y, Jin A, Li J, Lin Z.

Oncol Rep. 2017 Feb;37(2):857-864. doi: 10.3892/or.2016.5302. Epub 2016 Dec 8.

PMID:
27959420
9.

Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.

Liu C, Yang Z, Li D, Liu Z, Miao X, Yang L, Zou Q, Yuan Y.

Cancer Biomark. 2015;15(6):735-43. doi: 10.3233/CBM-150515.

PMID:
26406402
10.

Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.

Iakovlev V, Siegel ER, Tsao MS, Haun RS.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1135-42. doi: 10.1158/1055-9965.EPI-11-1079. Epub 2012 May 9.

11.

Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.

Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA.

PLoS One. 2014 Jun 16;9(6):e100178. doi: 10.1371/journal.pone.0100178. eCollection 2014.

12.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

13.

Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.

Zhang J, Jiang X, Zhang J.

World J Surg Oncol. 2014 Mar 1;12:49. doi: 10.1186/1477-7819-12-49.

14.

Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.

Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I.

Cancer Res. 2013 Apr 1;73(7):2357-67. doi: 10.1158/0008-5472.CAN-12-3359. Epub 2013 Jan 31.

15.

SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.

Shroff S, Rashid A, Wang H, Katz MH, Abbruzzese JL, Fleming JB, Wang H.

Hum Pathol. 2014 Mar;45(3):456-63. doi: 10.1016/j.humpath.2013.10.008. Epub 2013 Oct 19.

16.

Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.

Zhang K, Yao H, Yang Z, Li D, Yang L, Zou Q, Yuan Y, Miao X.

Clin Transl Oncol. 2016 Apr;18(4):352-9. doi: 10.1007/s12094-015-1331-x. Epub 2016 Feb 18.

PMID:
26887611
17.

NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.

Chen NM, Singh G, Koenig A, Liou GY, Storz P, Zhang JS, Regul L, Nagarajan S, Kühnemuth B, Johnsen SA, Hebrok M, Siveke J, Billadeau DD, Ellenrieder V, Hessmann E.

Gastroenterology. 2015 May;148(5):1024-1034.e9. doi: 10.1053/j.gastro.2015.01.033. Epub 2015 Jan 23.

18.

Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation.

Soini Y, Takasawa A, Eskelinen M, Juvonen P, Kärjä V, Hasegawa T, Murata M, Tanaka S, Kojima T, Sawada N.

J Clin Pathol. 2012 May;65(5):431-6. doi: 10.1136/jclinpath-2011-200400. Epub 2012 Mar 6.

PMID:
22396552
19.

CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.

Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS, Cha BH.

Pancreas. 2014 Apr;43(3):380-8. doi: 10.1097/MPA.0000000000000097.

PMID:
24622067
20.

Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.

Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B.

J Clin Pathol. 2008 Jan;61(1):49-58. Epub 2007 Apr 5.

PMID:
17412869

Supplemental Content

Support Center